EKF Diagnostics Investor Announcements
EKF Diagnostics Holdings plc is an in-vitro diagnostics (IVD) business. The Company is engaged in the designing, development, manufacture and selling of diagnostic analyzers, reagents and ancillary products. This activity takes place across several geographical locations which include the United Kingdom, United States of America, Germany, Poland and Russia.
EKF announces that the Board of EKF has been informed that on Thursday 28 April 2022, certain funds connected to Christopher Mills, Non-executive Chairman.
EKF confirms that the Annual Report and Accounts for the year ended 31 December 2021 and the Notice of the 2022 Annual General Meeting have now been published
EKF announces that it has purchased a further 200,000 of its ordinary shares at a price of 40 pence per share.
EKF announces that it has purchased a total of 500,000 of its ordinary shares at a price of 40.08 pence per share.
EKF announces that it has purchased a total of 725,000 of its ordinary shares at a price of 42.1552 pence per share.
EKF announces that it has purchased a total of 1,625,000 of its ordinary shares at a price of 42.4985 pence per share.
EKF announces that it has purchased a total of 1,000,000 of its ordinary shares at a price of 42.55 pence per share.
EKF announces that it has purchased a total of 2,000,000 of its ordinary shares at a price of 43.7125 pence per share.
EKF announces that it has purchased a total of 750,000 of its ordinary shares at a price of 44.1667 pence per share
EKF has purchased a total of 900,000 of its ordinary shares at a price of 44.6667 pence per share.
Newsletter
Keep up to date with all our activities, events, exhibitions, promotions, investor news & more.